Quarterly Results December 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.0 pts less than Nifty Microcap 250 and 2.7 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Gian Life Care reported a weak set of numbers for Q3 FY26 with revenue from operations of ₹112.28 lakhs, down from ₹158.86 lakhs in the year-ago quarter. For the nine months ended December 2025, revenue nearly halved to ₹264.98 lakhs from ₹551.76 lakhs in the same period last year. The company slipped into a loss of ₹28.54 lakhs (standalone) and ₹35.51 lakhs (consolidated) for the nine-month period, compared to profits of ₹63.18 lakhs and ₹56.12 lakhs respectively last year. The auditor issued a qualified review report, flagging an unverified cash balance of ₹743.78 lakhs along with unpaid statutory dues of ₹426.66 lakhs and a bank loan of ₹359.78 lakhs that has been classified as a Non-Performing Asset (NPA).
This is a negative filing for shareholders — collapsing revenues, a swing to loss, an NPA-tagged bank loan, unpaid statutory dues, and a qualified auditor opinion together raise serious concerns about the company's financial health and going-concern status. Investors should expect heightened risk and likely negative stock price reaction.